

ICKSH 2025 Poster List_Final

**** You can also check presentation date and final poster code on the 'My page → abstract submission'.
Before you visit the Poster Session room, please check it.**

Abstract No.	Code	Presentation Date (Only 1 day)	Topic	Title	Presenter	Country
AK-0074	PP01-1	March 27 (Thu.)	Acute Myeloid Leukemia	Reclassification of acute myeloid leukemia according to the 2022 World Health Organization classification and the international consensus classification using open-source data	Hee Jun Yun	Republic of Korea
AK-0079	PP01-2	March 27 (Thu.)	Acute Myeloid Leukemia	Ex vivo analysis of drug synergies for acute myeloid leukemia	Jamin Koo	Republic of Korea
AK-0085	PP01-3	March 27 (Thu.)	Acute Myeloid Leukemia	Serum is essential for in vitro long-term culture of primary acute myeloid leukemia leukapheresis peripheral blood cells	Dongchan Kim	Republic of Korea
AK-0097	PP01-4	March 27 (Thu.)	Acute Myeloid Leukemia	Combined astaxanthin and all-trans retinoic acid induces apoptosis in acute promyelocytic leukemia cell lines	DaBhin Kim	Republic of Korea
AK-0131	PP01-5	March 27 (Thu.)	Acute Myeloid Leukemia	Prognostic impact of FLT3-ITD mutated clone numbers in AML: A retrospective study	Daehun Kwag	Republic of Korea
AK-0133	PP01-6	March 27 (Thu.)	Acute Myeloid Leukemia	MECOM rearrangement in AML/MDS: Clinical characteristics and prognostic outcomes	So Yeon Park	Republic of Korea
AK-0134	PP01-7	March 27 (Thu.)	Acute Myeloid Leukemia	Therapeutic potential of genetically modified bacteria in an AML syngeneic mouse model	Su-young Choi	Republic of Korea
AK-0139	PP01-8	March 27 (Thu.)	Acute Myeloid Leukemia	Validation of prognostic scoring systems in older adults with acute myeloid leukemia undergoing intensive chemotherapy	Seonghan Lee	Republic of Korea
AO-0058	PP01-9	March 27 (Thu.)	Acute Myeloid Leukemia	Real-world experience with CPX-351 treatment for acute myeloid leukemia (AML) in England: Updated analysis of the cancer analysis system (CAS) database	Sung-Ho Beck	Republic of Korea
AO-0127	PP01-10	March 27 (Thu.)	Acute Myeloid Leukemia	Machine learning-driven integration of non-coding RNA splice variants to predict resistance to targeted therapies in relapsed/refractory acute myeloid leukemia	Sahnaz Vivinda Putri	Indonesia
AO-0193	PP01-11	March 27 (Thu.)	Acute Myeloid Leukemia	Navigating fusion genes discovery using deep transcriptome sequencing in acute myeloid leukaemia-normal karyotype patients	Angeli Ambayya	Malaysia
AO-0348	PP01-12	March 27 (Thu.)	Acute Myeloid Leukemia	The role of T cell receptors and subsets in relapse after hematopoietic stem cell transplantation in patients with acute myeloid leukemia: A systematic review and meta-analysis	Weiliang Zhang	China
AK-0020	PP01-13	March 27 (Thu.)	Acute Myeloid Leukemia	Unmet needs and the patient experience in chronic myeloid leukemia: Findings from the CML SUN survey in South Korean patients and physicians	Hawk Kim	Republic of Korea
AO-0149	PP01-14	March 28 (Fri.)	Acute Myeloid Leukemia	Effectiveness of azacitidine maintenance therapy in reducing the relapse in postallogeic HSCT in acute myeloid leukemia	Jatinkumar Veljibhai Dhanani	India
AO-0196	PP01-15	March 28 (Fri.)	Acute Myeloid Leukemia	Exploring dysregulated pathways in acute myeloid leukaemia-normal karyotype: a comprehensive analysis	ANGELI AMBAYYA	Malaysia
AO-0208	PP01-16	March 28 (Fri.)	Acute Myeloid Leukemia	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia using Haploidentical Donors in comparison to Matched Sibling Donors	Brijalkumar Patel	India
AO-0242	PP01-17	March 28 (Fri.)	Acute Myeloid Leukemia	Clinical study of Homoharringtonine combined with Venetoclax, Azacitidine and cytarabine in newly diagnosed acute myeloid leukemia.	Xin Yan	China
AO-0279	PP01-18	March 28 (Fri.)	Acute Myeloid Leukemia	SATB1 as a novel molecular player in pediatric acute myeloid leukemia pathogenesis	Harshita Makkar	India
AO-0345	PP01-19	March 28 (Fri.)	Acute Myeloid Leukemia	Outcome of newly diagnosed patients with AML treated with low-dose venetoclax in combination with CYP3A inhibitors and azacytidine in India	Gaurav Prakash	India
AO-0035	PP01-20	March 28 (Fri.)	Acute Myeloid Leukemia	Synergistic targeting of FLT3 and BCL-2 in FLT3/ITD acute myeloid leukemia: Benzothiazepine-based inhibitors inducing apoptosis via BIM activation	Rizki Rachmad Saputra	Indonesia
AO-0364	PP01-21	March 28 (Fri.)	Acute Myeloid Leukemia	Impact of marital status on prognosis in acute myeloid leukemia: A population-based analysis	Nadyatul Husna	Indonesia
AO-0175	PP01-22	March 28 (Fri.)	Acute Myeloid Leukemia	Molecular and clinical characterization of adult acute myeloid leukemia with recurrent genetic abnormalities: A DNA- and RNA-based next-generation sequencing analysis	Natthaporn Sasijareonrat	Thailand
AO-0329	PP01-23	March 28 (Fri.)	Acute Myeloid Leukemia	Synergistic effect of EZH2 inhibitor DZNeP and flavonoid GL-V9 in AML through inhibition HELLS and induction of DNA damage	Chan Yang	China
AO-0052	PP01-24	March 28 (Fri.)	Acute Myeloid Leukemia	Outcome of TP53 mutated Acute Myeloid leukemia and Myelodysplastic syndrome- case series	Pei Ling Low	Malaysia
AK-0159	PP01-25	March 28 (Fri.)	Acute Myeloid Leukemia	Impact of all-trans retinoic acid(ATRA) maintenance therapy on survival outcomes in acute promyelocytic leukemia	Kunye Kwak	Republic of Korea
AK-0053	PP02-1	March 27 (Thu.)	Myelodysplastic Syndrome	Diagnostic impact of newly-defined monocytosis in chronic myeloid neoplasms: real world data on reclassification and mutational characterization	Haesung Ryu	Republic of Korea
AK-0061	PP02-2	March 27 (Thu.)	Myelodysplastic Syndrome	Reclassification of myelodysplastic neoplasms according to the 2022 World Health Organization classification and the 2022 international consensus classification using open-source data: Focus on SF3B1- and TP53-mutated myelodysplastic	Jiwon Yun	Republic of Korea
AK-0103	PP02-3	March 27 (Thu.)	Myelodysplastic Syndrome	Prognostic implications of telomere length in myelodysplastic syndrome patients treated with hypomethylating agents	Hyunkyung Park	Republic of Korea

ICKSH 2025 Poster List_Final

**** You can also check presentation date and final poster code on the 'My page → abstract submission'.
Before you visit the Poster Session room, please check it.**

Abstract No.	Code	Presentation Date (Only 1 day)	Topic	Title	Presenter	Country
AO-0248	PP02-4	March 27 (Thu.)	Myelodysplastic Syndrome	Predictive value of post-transplantation measurable residual disease in patients with myelodysplastic syndrome: A prospective cohort study	Yuewen Wang	China
AO-0267	PP02-5	March 27 (Thu.)	Myelodysplastic Syndrome	Deep learning-driven decoding of cryptic splice variants in myelodysplastic syndromes using multi-omic single-cell data integration to predict transformation to acute myeloid leukemia	Rifaldy Fajar	Indonesia
AO-0106	PP02-6	March 28 (Fri.)	Myelodysplastic Syndrome	Deep learning-based discovery of aberrant RNA splicing patterns as predictive biomarkers for therapy resistance in myelodysplastic syndrome	Rifaldy Fajar	Indonesia
AO-0311	PP02-7	March 28 (Fri.)	Myelodysplastic Syndrome	SETBP-1 mutations favors transformation to AML in PTPN-11 positive JMML	Aditya Kumar Gupta	India
AO-0239	PP02-8	March 28 (Fri.)	Myelodysplastic Syndrome	Clinical outcome and determinants of immunosuppressive therapy in myelodysplastic syndromes	Nilamkumari Patel	India
AO-0297	PP02-9	March 28 (Fri.)	Myelodysplastic Syndrome	Expression profiling of MEGF6, RAP1GAP, CSF3R in hypomethylating agent (HMAs) resistance of myelodysplastic syndrome patients	Anindya Amanda Damayanti	Indonesia
AO-0308	PP02-10	March 28 (Fri.)	Myelodysplastic Syndrome	A prospective study to evaluate the efficacy and safety of hematopoietic stem cell transplantation in pediatric patients with myelodysplastic syndrome	Fayaz Ahmed Mubarak Ali	India
AO-0074	PP02-11	March 28 (Fri.)	Myelodysplastic Syndrome	Gene expression analysis in myelodysplastic syndrome: Insights from bioinformatics on upregulated and downregulated genes	Satria Akbar Putra Asmara	Indonesia
AK-0076	PP03-1	March 27 (Thu.)	Acute Lymphoblastic Leukemia	Characteristics and clinical outcome of adult patients with mixed phenotype acute leukemia (MPAL) treated with myeloid-derived therapeutic strategy	Jae-Ho Yoon	Republic of Korea
AK-0078	PP03-2	March 27 (Thu.)	Acute Lymphoblastic Leukemia	A study on the relationship between ex vivo drug sensitivity and clinical outcome of acute lymphoblastic leukemia	Jamin Koo	Republic of Korea
AO-0036	PP03-3	March 27 (Thu.)	Acute Lymphoblastic Leukemia	Dual inhibition of PI3K-delta and CXCR4 in pediatric acute lymphoblastic leukemia: 1,5-benzothiazepine derivatives with beta-cyclodextrin inclusion complex for enhanced therapeutic potential	Rizki Rachmad Saputra	Indonesia
AO-0125	PP03-4	March 27 (Thu.)	Acute Lymphoblastic Leukemia	Thromboprophylaxis in pediatric and adult ALL patients undergoing asparaginase treatment: A systematic review and meta-analysis	Muhammad Farid Rakhman	Indonesia
AO-0180	PP03-6	March 27 (Thu.)	Acute Lymphoblastic Leukemia	Expression of immune checkpoints PD-1 and PDL-1/PDL-2 in pediatric B-ALL: Implications for disease progression and immunotherapy	Gaurav Chhabra	India
AO-0022	PP03-7	March 28 (Fri.)	Acute Lymphoblastic Leukemia	Next-generation CAR-T cell therapy in ALL: Exploring enhanced persistence and reduced toxicity via gene editing	Pavithran Damodaran	India
AO-0299	PP03-8	March 28 (Fri.)	Acute Lymphoblastic Leukemia	Genomic landscape and diagnostic advancements in BCR-ABL1-like ALL: Identification of the novel RUNX1::FGF13 fusion and diagnostic panel development	JAY SINGH	India
AO-0042	PP03-9	March 28 (Fri.)	Acute Lymphoblastic Leukemia	Utility of anchored multiplex PCR and targeted sequencing in fusion detection in B-cell acute lymphoblastic leukemia (B-ALL)	Sanjeev Kumar Gupta	India
AO-0191	PP03-10	March 28 (Fri.)	Acute Lymphoblastic Leukemia	Comparison of dexamethasone and prednisolone in induction therapy of childhood acute lymphoblastic leukemia: A meta-analysis	Kailash Mani Pokhrel	Nepal
AO-0289	PP03-11	March 28 (Fri.)	Acute Lymphoblastic Leukemia	Evaluation of minimal residual disease by flow cytometry in pediatric B-cell acute leukemia patients after induction therapy and before maintenance therapy	Le Phuong Mai NGUYEN	Vietnam
AO-0034	PP03-12	March 28 (Fri.)	Acute Lymphoblastic Leukemia	Array-CGH reveals key genetic variations in Malaysian childhood acute lymphoblastic leukemia	Mohd Fadly Md Ahid	Malaysia
AO-0164	PP03-13	March 28 (Fri.)	Acute Lymphoblastic Leukemia	Experience with amplicon based next generation sequencing panels in pediatric hematological disorders: A 6-year patient care service data	Sharun Sharun	India
AK-0011	PP04-2	March 27 (Thu.)	Chronic Myeloid Leukemia	Incidence, prevalence, and real-world treatment patterns in chronic myeloid leukemia in Korea: A retrospective claims database analysis	Song Baik	Republic of Korea
AK-0128	PP04-3	March 27 (Thu.)	Chronic Myeloid Leukemia	Ponatinib as a second-line treatment for patients with chronic phase chronic myeloid leukemia (CML-CP) who have failed or are intolerant to first-line second-generation TKI therapy	Soyean Kwon	Republic of Korea
AK-0137	PP04-4	March 27 (Thu.)	Chronic Myeloid Leukemia	A more rapid initial decline of BCR::ABL1 transcripts and longer treatment duration with improvement of treatment-free remission rate after discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia	Sewon Lee	Republic of Korea
AK-0149	PP04-5	March 28 (Fri.)	Chronic Myeloid Leukemia	Validation of control genes for development of BCR::ABL1 fusion gene quantification kit based on droplet digital PCR system	Bong S. Kim	Republic of Korea
AO-0109	PP04-6	March 28 (Fri.)	Chronic Myeloid Leukemia	An overview of asciminib treatment in chronic myeloid leukaemia after ABL kinase inhibitor failure: A case series from Malaysia	Christopher Chin Keong Liam	Malaysia
AO-0124	PP04-7	March 28 (Fri.)	Chronic Myeloid Leukemia	Genetic variations, expression, and promoter methylation of the tumor suppressor gene in chronic myeloid leukemia: A study in the Indian population	Asgar Ali	India
AO-0099	PP04-8	March 28 (Fri.)	Chronic Myeloid Leukemia	Rapid and sensitive detection of BCR::ABL1 fusion gene in chronic myeloid leukemia using multiplex RT-Qpcr	Siti Rahayu Sabtu	Malaysia
AK-0022	PP05-1	March 27 (Thu.)	Lymphoma	Various clinical features and outcomes of histiocytic sarcoma patients	Gi June Min	Republic of Korea

ICKSH 2025 Poster List_Final

**** You can also check presentation date and final poster code on the 'My page → abstract submission'.
Before you visit the Poster Session room, please check it.**

Abstract No.	Code	Presentation Date (Only 1 day)	Topic	Title	Presenter	Country
AK-0023	PP05-2	March 27 (Thu.)	Lymphoma	Efficacy and safety of rituximab-based chemoimmunotherapy in Korean adult burkitt lymphoma patients	Gi June Min	Republic of Korea
AK-0026	PP05-3	March 27 (Thu.)	Lymphoma	Real-world outcomes of polatuzumab vedotin with bendamustine and rituximab as salvage and bridge therapy to CAR T-cell treatment in relapsed/refractory diffuse large B-cell lymphoma	Changgon Kim	Republic of Korea
AK-0029	PP05-4	March 27 (Thu.)	Lymphoma	Effectiveness of axi-cel and tisa-cel therapies for relapsed/refractory follicular lymphoma: External control study	Hee-Jin Seo	Republic of Korea
AK-0035	PP05-5	March 27 (Thu.)	Lymphoma	Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: Data from an ongoing phase 1/1b study BGB-11417-101	Hyungwoo Cho	Republic of Korea
AK-0042	PP05-6	March 27 (Thu.)	Lymphoma	Clinical outcomes and prognostic factors of colorectal ENMZL	Yeokyeong Shin	Republic of Korea
AK-0043	PP05-7	March 27 (Thu.)	Lymphoma	Clinical significance of Epstein-Barr virus (EBV) infection in peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)	Hyunseok Yoon	Republic of Korea
AK-0046	PP05-8	March 27 (Thu.)	Lymphoma	Interim PET for better prognostication of patients with extranodal natural killer/T-cell lymphoma treated with non-anthracycline containing L-asparaginase based regimen	Sojin Kim	Republic of Korea
AK-0048	PP05-9	March 27 (Thu.)	Lymphoma	Investigating EGR1's Contribution to Immune evasion in Extranodal natural killer/T-cell Lymphoma	Ji Yun Lee	Republic of Korea
AK-0049	PP05-10	March 27 (Thu.)	Lymphoma	Sequential Bruton tyrosine kinase inhibitor therapy in relapsed or refractory mantle cell lymphoma following chemotherapy: Real-world outcomes and attrition rates - An updated report from the Asia-Pacific multinational retrospective registry	Hyungwoo Cho	Republic of Korea
AK-0054	PP05-11	March 27 (Thu.)	Lymphoma	Efficacy of frontline regimens for Waldenstrom macroglobulinemia	Seo Yoon Jang	Republic of Korea
AK-0055	PP05-12	March 27 (Thu.)	Lymphoma	Indirect treatment comparison of brexucabtagene autoleucel versus conventional treatments for relapsed/refractory mantle cell lymphoma: An external comparator study using real-world data	JIN HEE KIM	Republic of Korea
AK-0056	PP05-13	March 27 (Thu.)	Lymphoma	Clinical usefulness of sequential circulating-tumor DNA analysis in patients with advanced stage diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy	Ga-Young Song	Republic of Korea
AK-0058	PP05-14	March 27 (Thu.)	Lymphoma	CD20-expressing tumor-derived microvesicles as mediators of resistance to rituximab in DLBCL patients	BON PARK	Republic of Korea
AK-0064	PP05-15	March 27 (Thu.)	Lymphoma	Clinical outcomes of tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma: Insights from a single center study	Sang Eun Yoon	Republic of Korea
AK-0080	PP05-16	March 27 (Thu.)	Lymphoma	Impact of consolidation treatment in patients with primary central nervous system lymphoma after R-MVP chemotherapy	Sang-A Kim	Republic of Korea
AK-0084	PP05-17	March 27 (Thu.)	Lymphoma	Prevalence and characteristics of germline predisposition mutations in lymphoma patients	Yu Jeong Choi	Republic of Korea
AK-0102	PP05-18	March 27 (Thu.)	Lymphoma	Real-world outcomes and prognostic factors in elderly DLBCL patients treated with R-CHOP: Insights for optimal management	Eun-Jeong Jeong	Republic of Korea
AK-0108	PP05-19	March 27 (Thu.)	Lymphoma	Outcomes of newly diagnosed pediatric T-cell lymphoblastic lymphoma: A matching-adjusted indirect comparison of conventional chemotherapy and bortezomib-containing regimens using real-world data as an external comparator	Yoona Choi	Republic of Korea
AK-0114	PP05-20	March 27 (Thu.)	Lymphoma	Genomic profiles from whole exome sequencing reflect clinical outcomes and temporal dynamics in chronic lymphocytic leukemia patients	Ho Cheol Jang	Republic of Korea
AK-0115	PP05-21	March 27 (Thu.)	Lymphoma	Duodenal-type follicular lymphoma in Korean population [DUOFOLK]	Jongheon Jung	Republic of Korea
AK-0140	PP05-22	March 27 (Thu.)	Lymphoma	Mutation of KM2A gene correlation with inferior outcomes in peripheral T-cell lymphoma	Tong Yoon Kim	Republic of Korea
AK-0143	PP05-23	March 27 (Thu.)	Lymphoma	Incidence of genomic alteration subtypes and inconsistent survival outcomes in Korean patients with DLBCL	Tong Yoon Kim	Republic of Korea
AK-0145	PP05-24	March 28 (Fri.)	Lymphoma	Elevation of 1,25-Dihydroxyvitamin D3 Predicts Inferior Outcomes in Non-Hodgkin Lymphoma	Tong Yoon Kim	Republic of Korea
AK-0156	PP05-25	March 28 (Fri.)	Lymphoma	Understanding the unmet needs in diagnosis and treatment of chronic lymphocytic leukemia in Korea	Eun Sang Yu	Republic of Korea
AK-0157	PP05-26	March 28 (Fri.)	Lymphoma	Prognostic value of 18F-FDG PET in primary central nervous system lymphoma: Assessing interim metabolic response for improving patient stratification	Ga-Young Song	Republic of Korea
AO-0012	PP05-27	March 28 (Fri.)	Lymphoma	Plasmablastic lymphoma in Taiwan is frequently associated with malignant effusion: A single institutional experience	Shih-Sung Chuang	Taiwan
AO-0060	PP05-28	March 28 (Fri.)	Lymphoma	Epcoritamab monotherapy in patients with relapsed or refractory large B-cell lymphoma not previously treated with CAR T: EPCORE NHL-1 subanalysis	Yasmin H. Karimi	United States
AO-0107	PP05-29	March 28 (Fri.)	Lymphoma	Epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma: 3-year results from the EPCORE NHL-1 trial	Won Seog Kim	Republic of Korea

ICKSH 2025 Poster List_Final

**** You can also check presentation date and final poster code on the 'My page → abstract submission'.
Before you visit the Poster Session room, please check it.**

Abstract No.	Code	Presentation Date (Only 1 day)	Topic	Title	Presenter	Country
AO-0137	PP05-30	March 28 (Fri.)	Lymphoma	Fixed-duration epcoritamab monotherapy in newly diagnosed, older, anthracycline-ineligible patients with large B-cell Lymphoma: First results from the EPCORE DLBCL-3 phase 2 trial	Won Seog Kim	Republic of Korea
AO-0138	PP05-31	March 28 (Fri.)	Lymphoma	High complete response rates with fixed-duration epcoritamab + R-CHOP in patients with previously untreated diffuse Large B-cell lymphoma: EPCORE NHL-2 long-term results	Lorenzo Falchi	United States
AO-0254	PP05-32	March 28 (Fri.)	Lymphoma	Golcadomide plus R-CHOP has high minimal residual disease-negativity (MRD-) across high risk, untreated aggressive B-cell lymphoma (a-BCL): Phase 1b CC-220-DLBCL-001 study data	Won Seog Kim	Republic of Korea
AO-0255	PP05-33	March 28 (Fri.)	Lymphoma	Golcadomide monotherapy (G) and golcadomide plus rituximab (G+R) demonstrate durable efficacy and are well tolerated in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Update from the phase 1/2 CC-	Won Seog Kim	Republic of Korea
AO-0262	PP05-34	March 28 (Fri.)	Lymphoma	Machine learning-based prediction of myeloid-derived suppressor cell expansion in HIV-associated Hodgkin lymphoma: Decoding immune dysregulation through integrative single-cell transcriptomics	Sahnaz Vivinda Putri	Indonesia
AO-0265	PP05-35	March 28 (Fri.)	Lymphoma	TP53 mutations with low variant allele frequency (VAF) characterize a distinct subgroup in CLL with favorable outcomes to targeted agents	Daniel Sungchul Choi	United States
AO-0365	PP05-36	March 28 (Fri.)	Lymphoma	Tumor mutation burden (TMB) and a novel somatic mutation in the TREX1 gene in a patient with aggressive and refractory high-grade B-cell lymphoma: Case report	Mariia Gusakova	Russia
AO-0101	PP05-37	March 28 (Fri.)	Lymphoma	Positron emission tomography (PET)-adapted Strategy in advanced classic Hodgkin lymphoma: maximizing efficacy; reducing toxicity	Yang Liang Boo	Malaysia
AO-0104	PP05-38	March 28 (Fri.)	Lymphoma	Limited-stage classical Hodgkin lymphoma (cHL): Combined modality treatment vs chemotherapy alone in real-world setting	Xin Wei Choo	Malaysia
AO-0112	PP05-39	March 28 (Fri.)	Lymphoma	Real-world patient clinical profiles, treatment pattern and outcomes of classic Hodgkin lymphoma: A retrospective database review in a Malaysian tertiary centre	KAI XIN ANG	Malaysia
AO-0227	PP05-40	March 28 (Fri.)	Lymphoma	Evaluating the prognostic significance of platelet count in patients with diffuse large B cell lymphoma in the rituximab era: A meta-analysis	Rukesh Yadav	Nepal
AO-0156	PP05-42	March 28 (Fri.)	Lymphoma	Assessing the real-world diagnostic utility of T-cell receptor clonality assays for challenging T-cell lymphoproliferative disorders in formalin-fixed paraffin-embedded tissues	Pulkrit Rastogi	India
AO-0384	PP05-43	March 28 (Fri.)	Lymphoma	Correlation of cell-free DNA with various PET based parameters and treatment response in patients with DLBCL	Anu Kumari	India
AO-0216	PP05-44	March 28 (Fri.)	Lymphoma	Characteristics and outcomes of patients with Hodgkin lymphoma with paraneoplastic manifestations	Gaurav Prakash	India
AO-0033	PP05-45	March 28 (Fri.)	Lymphoma	Cytological features of an EBV-positive Nodal T/NK-cell lymphoma	Shih-Sung Chuang	Taiwan
AK-0017	PP06-1	March 27 (Thu.)	Histiocytosis and Other Dendritic Cell Neoplasms	Single-cell immune landscape in patients with malignancy-associated hemophagocytic lymphohistiocytosis	Jeong-Eun Kwak	Republic of Korea
AO-0110	PP06-2	March 28 (Fri.)	Histiocytosis and Other Dendritic Cell Neoplasms	Epigenetic profiling and therapeutic target discovery in Rosai-Dorfman disease and related histiocytic disorders: A deep learning multi-omics approach	Prihantini Prihantini	Indonesia
AK-0008	PP07-1	March 27 (Thu.)	Multiple Myeloma	Evaluation of the preventive effect of rosuvastatin exposure on multiple myeloma progression from MGUS [CAREMM-2110]	Suein Choi	Republic of Korea
AK-0010	PP07-2	March 27 (Thu.)	Multiple Myeloma	Risk-benefit analysis of bisphosphonate treatment in relation to exposure levels: Osteonecrosis of the jaw and fracture risks in multiple myeloma patients [CAREMM-2111]	Seungpil Jung	Republic of Korea
AK-0014	PP07-3	March 27 (Thu.)	Multiple Myeloma	Cost-effectiveness analysis of daratumumab monotherapy and subsequent therapies in heavily treated relapsed/refractory multiple myeloma: A feasible methodology using a Korean nationwide population cohort	Sung-Soo Park	Republic of Korea
AK-0015	PP07-4	March 27 (Thu.)	Multiple Myeloma	Different levels and difficulties of the financial burden in patients with multiple myeloma and their caregivers: A dyadic qualitative study	YoungJu Park	Republic of Korea
AK-0024	PP07-5	March 27 (Thu.)	Multiple Myeloma	Development and validation of a multiple myeloma-specific comorbidity index from a Korean nationwide cohort: CAREMM-2108	Si Eun Oh	Republic of Korea
AK-0025	PP07-6	March 27 (Thu.)	Multiple Myeloma	Comparison of tandem autologous stem cell transplantation, maintenance therapy, and no subsequent treatment in MRD positive multiple myeloma patients post-ASCT	Si Eun Oh	Republic of Korea
AK-0030	PP07-7	March 27 (Thu.)	Multiple Myeloma	NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma	SOJEONG KIM	Republic of Korea
AK-0031	PP07-8	March 27 (Thu.)	Multiple Myeloma	Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma	Soyean Kwon	Republic of Korea
AK-0034	PP07-9	March 27 (Thu.)	Multiple Myeloma	Prognostic impact and clinical features of t(11;14) in multiple myeloma	Jung-Un Nam	Republic of Korea
AK-0057	PP07-10	March 27 (Thu.)	Multiple Myeloma	Exosomal miR-144-3p targets fibronectin and mTOR: A prognostic biomarker for poor outcomes in multiple myeloma	Kyung Ju Ryu	Republic of Korea
AK-0060	PP07-11	March 27 (Thu.)	Multiple Myeloma	Beneficial impact of early diagnosis of multiple myeloma from monoclonal gammopathy of undetermined significance: The CAREMM-2307 study	Ka Young Kim	Republic of Korea

ICKSH 2025 Poster List_Final

**** You can also check presentation date and final poster code on the 'My page → abstract submission'.
Before you visit the Poster Session room, please check it.**

Abstract No.	Code	Presentation Date (Only 1 day)	Topic	Title	Presenter	Country
AK-0063	PP07-12	March 27 (Thu.)	Multiple Myeloma	Randomized phase II study of bortezomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in elderly patients with newly diagnosed multiple Myeloma (KMM1910)	Sang Eun Yoon	Republic of Korea
AK-0067	PP07-13	March 27 (Thu.)	Multiple Myeloma	Indirect treatment comparisons of daratumumab-pomalidomide-dexamethasone and pomalidomide-bortezomib-dexamethasone in relapsed/refractory multiple myeloma	Sung-Hoon Jung	Republic of Korea
AK-0071	PP07-14	March 28 (Fri.)	Multiple Myeloma	Pooled efficacy and safety of teclistamab in 217 patients with triple-class exposed relapsed/refractory multiple myeloma from 3 registrational clinical studies	Angeline Zhu	Singapore
AK-0095	PP07-15	March 28 (Fri.)	Multiple Myeloma	Belantamab Mafodotin+Bortezomib+Dexamethasone (BVD) vs Daratumumab+Vd (DVD) in RRMM: Updates on Overall Survival (OS) and Efficacy in DREAMM-7	Kihyun Kim	Republic of Korea
AK-0099	PP07-16	March 28 (Fri.)	Multiple Myeloma	Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma	Ji Hyun Lee	Republic of Korea
AK-0100	PP07-17	March 28 (Fri.)	Multiple Myeloma	Clinical characteristics and outcomes of primary and secondary multiple myeloma: A single-center retrospective study	Chulkue Pak	Republic of Korea
AK-0111	PP07-18	March 28 (Fri.)	Multiple Myeloma	Characterization of mutation profile in multiple myeloma: Comparison of NGS with G-banding and FISH	Suji Park	Republic of Korea
AK-0129	PP07-19	March 28 (Fri.)	Multiple Myeloma	Prognostic implications of cytogenetic high-risk abnormalities and minimal residual disease in newly diagnosed multiple myeloma	Ari Ahn	Republic of Korea
AK-0150	PP07-20	March 28 (Fri.)	Multiple Myeloma	Phase II study of carfilzomib, pomalidomide, and dexamethasone (KPd) for multiple myeloma patients who had relapsed or progressed after carfilzomib, lenalidomide, and dexamethasone (KRd)	Jun Ho Yi	Republic of Korea
AO-0046	PP07-21	March 28 (Fri.)	Multiple Myeloma	Multiple myeloma presenting with myelomatous pleural effusion: Report of a case	Shih-Sung Chuang	Taiwan
AO-0132	PP07-22	March 28 (Fri.)	Multiple Myeloma	Decoding extrachromosomal DNA (ecDNA)-mediated transcriptional dysregulation in high-risk multiple myeloma: A machine learning-driven multi-omics approach	Elfiany Syafruddin	Indonesia
AO-0105	PP07-23	March 28 (Fri.)	Multiple Myeloma	Impact of NRAS, KRAS, BRAF gene polymorphism on the course of multiple myeloma	Zhanna Kozich	Belarus
AO-0032	PP07-24	March 28 (Fri.)	Multiple Myeloma	Icariin as a modulator of STAT3 Activation: Implications for multiple myeloma therapy	GAUTAM SETHI	Singapore
AO-0071	PP07-25	March 28 (Fri.)	Multiple Myeloma	Real world daratumumab survival outcomes in heavily pre treated Asian patients with relapsed/refractory multiple myeloma	Carol Goh Chew Yuen	Malaysia
AO-0330	PP07-26	March 28 (Fri.)	Multiple Myeloma	Unveiling unique protein signatures in bone marrow stromal cells linked to poor therapeutic response in multiple myeloma	Aishwarya Dash	India
AK-0090	PP07-27	March 28 (Fri.)	Multiple Myeloma	Development of a personalized microfluidic platform for multiple myeloma patients	Seohee You	Republic of Korea
AK-0016	PP08-1	March 27 (Thu.)	Myeloproliferative Neoplasm	Central arterial stiffness in patients with newly diagnosed essential thrombocythemia	Deog-Yeon Jo	Republic of Korea
AK-0072	PP08-2	March 27 (Thu.)	Myeloproliferative Neoplasm	Distinct factors influence on complete hematological response maintenance in polycythemia vera patients treated with Ropeginterferon alfa-2b	Sung-Eun Lee	Republic of Korea
AK-0075	PP08-3	March 27 (Thu.)	Myeloproliferative Neoplasm	Predicting molecular response through half reduction of neutrophil-to-lymphocyte ratio (NLR) in polycythemia vera treatment with ropeginterferon	Seug Yun Yoon	Republic of Korea
AO-0243	PP08-4	March 28 (Fri.)	Myeloproliferative Neoplasm	Real world data for ruxolitinib in adult patients with myelofibrosis and/or polycythemia vera: A post-marketing surveillance study in Korea	Sung-Eun Lee	Republic of Korea
AO-0302	PP08-5	March 28 (Fri.)	Myeloproliferative Neoplasm	Delayed healing of femoral fracture and treatment obstacle in geriatric patient with polycythemia: A case report with literature review	Danan Budi Primadi	Indonesia
AK-0112	PP09-1	March 27 (Thu.)	Bone Marrow Failure Syndromes	Diamond-Blackfan anemia syndrome in Gwangju-Chonnam province, South Korea: Clinical manifestations and long-term real-world follow-up of 12 cases	Bo Ram Kim	Republic of Korea
AK-0135	PP09-2	March 27 (Thu.)	Bone Marrow Failure Syndromes	Upregulation of TIM3 on bone marrow-infiltrating T cells in early relapses of hematologic malignancies after hematopoietic stem cell transplantation	Thi Thuy Duong Pham	Republic of Korea
AK-0146	PP09-3	March 28 (Fri.)	Bone Marrow Failure Syndromes	Prognosis after allogeneic stem cell transplantation in old age patients with myelofibrosis	Dae-Ho Choi	Republic of Korea
AK-0032	PP10-1	March 27 (Thu.)	Laboratory Hematology	Transcript-specific quantification and detection bias of BCR-ABL1 in patients with chronic myeloid leukemia using droplet digital polymerase chain reaction	Hyunji Kim	Republic of Korea
AK-0045	PP10-2	March 27 (Thu.)	Laboratory Hematology	Atypical lymphocytosis induced by T cell-engaging therapies	Tae-Shin Kim	Republic of Korea
AK-0087	PP10-3	March 27 (Thu.)	Laboratory Hematology	Evaluation of two plasma cell sorting methods for genetic testing of plasma cell neoplasm	Yu Jeong Choi	Republic of Korea
AK-0118	PP10-4	March 27 (Thu.)	Laboratory Hematology	Streamlined and reliable dimensionality reduction-based gating in flow cytometry for hematologic malignancies	Min-Seung Park	Republic of Korea

ICKSH 2025 Poster List_Final

**** You can also check presentation date and final poster code on the 'My page → abstract submission'.
Before you visit the Poster Session room, please check it.**

Abstract No.	Code	Presentation Date (Only 1 day)	Topic	Title	Presenter	Country
AK-0124	PP10-5	March 27 (Thu.)	Laboratory Hematology	Immunoglobulin gene repertoire and immunoglobulin heavy chain variable gene somatic hypermutation profiling in Korean patients with chronic lymphocytic leukemia using next-generation sequencing	Taegeun Lee	Republic of Korea
AK-0125	PP10-6	March 27 (Thu.)	Laboratory Hematology	Evaluation of leukocyte discrimination performance of PBIA-12A automated blood digital image analysis system	JeeHey Kim	Republic of Korea
AK-0138	PP10-7	March 27 (Thu.)	Laboratory Hematology	Point-of-care coagulometer as a potential tool for factor VIII measurement	Yoonseo Jung	Republic of Korea
AK-0155	PP10-8	March 27 (Thu.)	Laboratory Hematology	Pilot evaluation of the KAPA HyperCap DS NHL panel for circulating tumor DNA-based measurable residual disease monitoring in diffuse large B-cell lymphoma	Hyun-Young Kim	Republic of Korea
AK-0160	PP10-9	March 27 (Thu.)	Laboratory Hematology	Automated immature granulocyte count by Sysmex XN analyzer: a comparison with manual count and characterization of erroneous	Young-Uk Cho	Republic of Korea
AO-0129	PP10-10	March 27 (Thu.)	Laboratory Hematology	Evaluation of three-color panel for detection of paroxysmal nocturnal haemoglobinuria by flow cytometry	Abhishek Purohit	India
AO-0273	PP10-11	March 28 (Fri.)	Laboratory Hematology	A novel artificial intelligence-based approach for early screening of acute leukemia in resource-limited settings	Sejal Mehta	India
AO-0047	PP10-12	March 28 (Fri.)	Laboratory Hematology	Detection of residual leukemic cells in ALL: A practical FISH approach on CSF	NARINE GHAZARYAN	Armenia
AO-0251	PP10-13	March 28 (Fri.)	Laboratory Hematology	Developing a process for analyzing CYP2C9 and VKORC1 gene polymorphisms in Vietnamese patients undergoing warfarin therapy	Thi-Nga Nguyen	Vietnam
AO-0020	PP10-14	March 28 (Fri.)	Laboratory Hematology	Phenotypic expression of hemoglobin hope and hemoglobin A2 in hemoglobin hope heterozygotes with different forms of alpha-thalassemia: Implications for alpha-thalassemia screening	Sitthichai Panyasai	Thailand
AO-0143	PP10-15	March 28 (Fri.)	Laboratory Hematology	The effectiveness of HPLC-premier resolution system in identifying hemoglobin constant spring and hemoglobin pakse	Surada Satthakarn	Thailand
AO-0097	PP10-16	March 28 (Fri.)	Laboratory Hematology	BaMBo & BoMBR: Deep learning datasets for bone marrow diagnostics with semantic segmentation and reticulin fiber quantification	Praveen Sharma	India
AO-0118	PP10-17	March 28 (Fri.)	Laboratory Hematology	Prevention of ubiquitin E3 ligase formation, SCF complex, is critical for RPS4X-mediated stabilization of host anti-apoptotic BCL-2 family proteins	Satsuki Ryu	Japan
AO-0209	PP10-18	March 28 (Fri.)	Laboratory Hematology	Unique hematological aspects of gilbert syndrome (UGT1A1*28/*28): Increased hemoglobin and protective effect on sodium metabisulfite-induced erythrocyte injury	Mugdha Gautam	India
AK-0019	PP10-19	March 28 (Fri.)	Laboratory Hematology	Diagnostic and prognostic utility of monocyte cell population data in patients with suspected sepsis	Hyejung Lee	Republic of Korea
AK-0126	PP10-20	March 28 (Fri.)	Laboratory Hematology	White blood cell count, neutrophil-to-lymphocyte ratio, and serum lactate dehydrogenase level as predictors of thrombosis risk in essential thrombocythemia: A Korean population study	Yu Been Oh	Republic of Korea
AK-0018	PP11-1	March 27 (Thu.)	Anemia and Other Red Cell Disorders	Transfusion avoidance with EPYSQLI (SB12): A post-hoc analysis from the pivotal phase III study	Jihyun Han	Republic of Korea
AK-0052	PP11-2	March 27 (Thu.)	Anemia and Other Red Cell Disorders	Mean corpuscular volume as a prognostic marker in patients with non-small cell lung cancer undergoing surgical resection	Wankyuo Eo	Republic of Korea
AO-0136	PP11-3	March 27 (Thu.)	Anemia and Other Red Cell Disorders	Mathematical modeling of ferroptosis-regulated erythropoiesis in sickle cell disease: A predictive framework for vaso-occlusive crisis onset	Rifaldy Fajar	Indonesia
AO-0160	PP11-4	March 27 (Thu.)	Anemia and Other Red Cell Disorders	Cost-effective molecular diagnosis in assessing the prevalence and impact of red cell enzyme disorders in metabolic pathways: An Indian perspective	Kajal Kajal	India
AO-0249	PP11-5	March 27 (Thu.)	Anemia and Other Red Cell Disorders	Vitamin B12 deficiency in breast fed infants: A hospital based cross sectional study from a LMIC	Nishant Verma	India
AO-0342	PP11-6	March 28 (Fri.)	Anemia and Other Red Cell Disorders	Systematic literature review: Effects of different forms of iron supplementation on gut microbiota composition and immune function in children with iron deficiency anemia	Ardita Faradhika	Indonesia
AO-0185	PP11-7	March 28 (Fri.)	Anemia and Other Red Cell Disorders	Uncovering plasmodium falciparum persistence in erythroblasts of G6PD-deficient hosts	Kanyarat Boonpeng	Thailand
AO-0201	PP11-8	March 28 (Fri.)	Anemia and Other Red Cell Disorders	Next-generation sequencing uncovers genetic mutations underlying Glucose-6-phosphate deficiency in Sri Lanka	Ruwindi Silva	Sri Lanka
AO-0218	PP11-9	March 28 (Fri.)	Anemia and Other Red Cell Disorders	Lessons learnt from 25 years experience of prenatal diagnosis for beta thalassemia from North India	Reena Das	India
AO-0220	PP11-10	March 28 (Fri.)	Anemia and Other Red Cell Disorders	Association between FGF23 and anemia in hemodialysis patients with diabetes type 1	Volha Vasilkova	Belarus
AO-0148	PP11-11	March 28 (Fri.)	Anemia and Other Red Cell Disorders	Epidemiology and cutaneous manifestations of sickle cell anemia: Transfusion challenges in resource-limited settings in Nepal	Shambhu Joshi	Nepal
AK-0040	PP12-1	March 27 (Thu.)	Platelet/Hemostasis	Desensitization and immune tolerance induction with combined immune modulation in hemophilia B patient with inhibitor	Young-Shil Park	Republic of Korea

ICKSH 2025 Poster List_Final

**** You can also check presentation date and final poster code on the 'My page → abstract submission'.
Before you visit the Poster Session room, please check it.**

Abstract No.	Code	Presentation Date (Only 1 day)	Topic	Title	Presenter	Country
AK-0110	PP12-2	March 27 (Thu.)	Platelet/Hemostasis	Enhancing diagnostic accuracy in thrombotic conditions: The role of fibrin degradation product alongside D-dimer testing	Daehyun Chu	Republic of Korea
AO-0145	PP12-3	March 27 (Thu.)	Platelet/Hemostasis	Mathematical modeling of platelet glycoalyx degradation in predicting thromboinflammatory events: A personalized antithrombotic approach	Prihantini Prihantini	Indonesia
AO-0165	PP12-4	March 27 (Thu.)	Platelet/Hemostasis	Active compound screening from moringa oleifera Lam.Leaves targeting Human P2Y12 purinergic receptor: A computational and in vitro approach	Krai Daowtak	Thailand
AO-0198	PP12-5	March 27 (Thu.)	Platelet/Hemostasis	Oleamide as an antiplatelet properties via collagen receptor glycoprotein VI	Nungruthai Nilsri	Thailand
AO-0200	PP12-6	March 27 (Thu.)	Platelet/Hemostasis	Unveiling the genetic basis using targeted resequencing-based approach of von Willebrand disease in North Indian patients: Genotype-phenotype correlation	Vasant Kumar	India
AO-0113	PP12-7	March 27 (Thu.)	Platelet/Hemostasis	Harnessing machine learning to predict rituximab response in pediatric immune thrombocytopenia patients: A path to personalized medicine	Jingyao Ma	China
AO-0285	PP12-8	March 27 (Thu.)	Platelet/Hemostasis	Rituximab treatment failure in pediatric ITP: Insights from single-cell sequencing of PBMCs	Lin Zheyang	China
AO-0301	PP12-9	March 28 (Fri.)	Platelet/Hemostasis	A comparison of my precise dose and WAPPS-Hemo as dosing tools for optimizing prophylaxis in children with hemophilia A treated with BAY 81-8973	Yaohan Zhou	China
AO-0069	PP12-10	March 28 (Fri.)	Platelet/Hemostasis	Platelet-specific deletion of TGF-β1 inhibits microvascular thrombosis in sepsis	Jianlin Qiao	China
AO-0096	PP12-12	March 28 (Fri.)	Platelet/Hemostasis	Extracellular vesicles-derived microRNAs fraction levels predict the development of thrombocytopenia in malaria infection	Duangdao Palasuwan	Thailand
AO-0120	PP12-13	March 28 (Fri.)	Platelet/Hemostasis	Innovative rice-starch films embedded with procoagulant peptides as a hemostatic material for wound management	Montira Chuahom	Thailand
AO-0300	PP12-14	March 28 (Fri.)	Platelet/Hemostasis	The comparison of immune tolerance induction and emicizumab prophylaxis in severe hemophilia children with inhibitors	Zhengping Li	China
AO-0098	PP12-15	March 28 (Fri.)	Platelet/Hemostasis	Effectiveness of sirolimus in early on-set autoimmune cytopenias of autoimmune lymphoproliferative immunodeficiencies (ALPIDs)	Hao Gu	China
AK-0094	PP13-1	March 27 (Thu.)	Hematopoietic Stem Cell Transplantation	Analysis of the effect of vaccination after autologous hematopoietic stem cell transplantation	Mi-ran Han	Republic of Korea
AO-0377	PP13-2	March 27 (Thu.)	Hematopoietic Stem Cell Transplantation	Hemorrhagic cystitis in pediatric severe aplastic anemia undergoing haploidentical hematopoietic stem cell transplantation: Incidence, risk factors and outcomes	Kai Cui	China
AO-0144	PP13-3	March 27 (Thu.)	Hematopoietic Stem Cell Transplantation	Therapeutic interventions during post-transplant neutropenia period affect myeloid-derived suppressor cell counts in multiple myeloma patients	Egor Batorov	Russia
AO-0235	PP13-4	March 27 (Thu.)	Hematopoietic Stem Cell Transplantation	Effect of plerixafor on neutrophil and platelet engraftment in patients undergoing stem cell transplant with preharvest CD34 count above 20 cells/mm3	Perraju Bhaskar Bhuvan Lagudu	India
AO-0236	PP13-5	March 27 (Thu.)	Hematopoietic Stem Cell Transplantation	Outcomes of stem cell transplantation from a Tier 2 city in lower middle-income countries (LMIC)- A retrospective study from a single center in South India	Perraju Bhaskar Bhuvan Lagudu	India
AO-0312	PP13-6	March 27 (Thu.)	Hematopoietic Stem Cell Transplantation	Pre harvest platelet counts predict response to plerixafor in pediatric patients undergoing autologous stem cell transplant	Aditya Kumar Gupta	India
AO-0313	PP13-7	March 27 (Thu.)	Hematopoietic Stem Cell Transplantation	Cytokine release syndrome after post haploidentical peripheral blood stem cell transplant incidence and outcomes	Aditya Kumar Gupta	India
AO-0374	PP13-8	March 27 (Thu.)	Hematopoietic Stem Cell Transplantation	Lower pre-conditioning absolute lymphocyte counts are associated with Worse outcomes in haploidentical hematopoietic stem cell transplantation with myeloablative regimen in children	Kai Cui	China
AO-0151	PP13-9	March 28 (Fri.)	Hematopoietic Stem Cell Transplantation	The obstacles and key influential factors while considering hematopoietic stem cell transplant (HSCT) by patients: A study of pre-HSCT acute leukaemia patients	Shweta Dhanani	India
AO-0190	PP13-10	March 28 (Fri.)	Hematopoietic Stem Cell Transplantation	Cytarabine transporter gene polymorphisms are associated with cytomegalovirus infection and hemorrhagic cystitis after HSCT in pediatric AML	Qi Ji	China
AO-0347	PP13-11	March 28 (Fri.)	Hematopoietic Stem Cell Transplantation	Deep learning-based integration of cell-free DNA fragmentomics and epigenomic signatures for early detection of relapse in post-transplant lymphoproliferative disorders	Prihantini Prihantini	Indonesia
AO-0094	PP13-12	March 28 (Fri.)	Hematopoietic Stem Cell Transplantation	Factor related mortality in patients undergoing HSCT center for international blood and marrow transplant research (CIBMTR)	Derizal Derizal	Indonesia
AO-0234	PP13-13	March 28 (Fri.)	Hematopoietic Stem Cell Transplantation	Outcomes of cost-effective autologous stem cell transplant in Indian patients - A retrospective study	Perraju Bhaskar Bhuvan Lagudu	India
AO-0176	PP13-14	March 28 (Fri.)	Hematopoietic Stem Cell Transplantation	Clinical analysis of the therapeutic effect of umbilical cord blood transplantation in 5 cases of mucopolysaccharidosis Type II	Yongping Zhang	China
AO-0309	PP13-15	March 28 (Fri.)	Hematopoietic Stem Cell Transplantation	A prospective study to investigate the role of extracellular vesicles as biomarkers in hematopoietic stem cell transplant outcomes	Aashal Bhavesh Shah	India

ICKSH 2025 Poster List_Final

**** You can also check presentation date and final poster code on the 'My page → abstract submission'.
Before you visit the Poster Session room, please check it.**

Abstract No.	Code	Presentation Date (Only 1 day)	Topic	Title	Presenter	Country
AO-0026	PP13-16	March 28 (Fri.)	Hematopoietic Stem Cell Transplantation	Enhancing HSCT success through microbiome engineering: gut microbiota modulation to prevent graft-versus-host disease	Pavithran Damodaran	India
AO-0133	PP14-1	March 27 (Thu.)	Hematopoiesis/Stem Cell Biology	Decoding ferroptosis-associated cell-free microRNA networks as predictors of stem cell clonality shift in clonal hematopoiesis using multi-modal machine learning models	Sahnaz Vivinda Putri	Indonesia
AO-0161	PP14-2	March 27 (Thu.)	Hematopoiesis/Stem Cell Biology	Damage to bone marrow stroma induced by gamma-radiation of a recipient is a prerequisite for engraftment of donor's MSCs injected intravenously	Aleksei Bigildeev	Russia
AO-0147	PP14-3	March 28 (Fri.)	Hematopoiesis/Stem Cell Biology	Effect of plasmodium falciparum-infected erythrocytes and their derived extracellular vesicles on megakaryopoiesis and thrombopoiesis	Nuntiporn Nunthanasup	Thailand
AO-0261	PP14-4	March 28 (Fri.)	Hematopoiesis/Stem Cell Biology	A multi-omics and machine learning approach to explore the epigenetic impact of hormone therapy on hematopoietic stem cells and hematologic disorders	Elfiany Syafruddin	Indonesia
AK-0127	PP15-1	March 27 (Thu.)	Cellular Therapy	Cytotoxicity and surface marker analysis of CRISPR-Cas9-mediated PD-1 knockout iPSC-derived NK cells	Sang-Woo Lee	Republic of Korea
AK-0082	PP16-1	March 27 (Thu.)	Transfusion Medicine	Effect of transfusion of fresh frozen plasma on coagulation Test: A single center study	Hee Sue Park	Republic of Korea
AO-0182	PP16-2	March 27 (Thu.)	Transfusion Medicine	Decoding transfusion-induced immune modulation in transgender individuals receiving gender-affirming hormone therapy: A machine learning multi-omics study	Sahnaz Vivinda Putri	Indonesia
AO-0223	PP16-3	March 27 (Thu.)	Transfusion Medicine	Determination of extracellular vesicles concentration in blood transfusion laboratory	Attakorn Palasuwan	Thailand
AO-0038	PP16-4	March 28 (Fri.)	Transfusion Medicine	Efficacy of acetaminophen and diphenhydramine vs. corticosteroid in preventing allergic transfusion reaction: Update meta-analysis	Bastomy Rezkit	Indonesia
AO-0043	PP16-5	March 28 (Fri.)	Transfusion Medicine	Dose-optimizing sodium pyrophosphate in PPDA-1 with CPDA-1 as a control to inhibit platelet clumping in whole blood storage	Judy Anne Bautista-Libu	Philippines
AO-0067	PP16-6	March 28 (Fri.)	Transfusion Medicine	Microfluidic chip for Rh-E antigen typing towards safe blood transfusion	Nang Noon Shean Aye	Thailand
AO-0027	PP16-7	March 28 (Fri.)	Transfusion Medicine	AI-guided pathogen reduction systems in blood transfusion: Enhancing blood safety and reducing adverse reactions	Pavithran Damodaran	India
AK-0070	PP17-1	March 27 (Thu.)	Others	Subcutaneous daratumumab (DARA) + bortezomib, cyclophosphamide, and dexamethasone (VCD) in patients with newly diagnosed light-chain (AL) amyloidosis: Overall survival and final major organ deterioration–progression-free	Efstathios Kastiris	Greece
AK-0109	PP17-2	March 27 (Thu.)	Others	Novel insights into DDX41 V152G mutation: RNA splicing disruption and tumorigenesis potential	Eun-Hye Hur	Republic of Korea
AK-0113	PP17-3	March 27 (Thu.)	Others	Reslizumab as a treatment for idiopathic hypereosinophilic syndrome: A pediatric case report	Hyoung Soo Choi	Republic of Korea
AK-0121	PP17-4	March 28 (Fri.)	Others	Utilizing artificial intelligence for differentiating band cells and mature neutrophils in canine peripheral blood smears	Minji Kim	Republic of Korea
AO-0294	PP17-5	March 28 (Fri.)	Others	Direct oral anticoagulants vs warfarin in antiphospholipid syndrome: A meta-analysis of thrombotic and bleeding outcomes	MADHUR BHATTARAI	Nepal
AO-0306	PP17-6	March 28 (Fri.)	Others	Chronic lymphocyte leukemia (CLL) treated with rituximab and bendamustine at Abidjan Cote D'Ivoire	Boidy KOUAKOU	Cote D'Ivoire
AO-0338	PP17-7	March 28 (Fri.)	Others	Setting reference values for whole blood count parameters using indirect methods in Burkina Faso: A preliminary study	Koumpingnin NEBIE	Burkina Faso
AO-0087	PP18-1	March 27 (Thu.)	Quality of Life	The relationship between neutrophil to lymphocyte ratio with duration of hospitalization, quality of life, and depression status in chronic myeloid leukemia patient	Rafik Prabowo	Indonesia
AO-0405	PP18-2	March 28 (Fri.)	Quality of Life	Evaluation of knowledge, attitudes, realities, and perspectives influencing blood donation motivation among university students in Delhi, India	Pardeep Kumar	India